Stocks · News reference
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:01 PM
- Checked
- Jul 20, 2026, 12:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — HALOZYME THERAPEUTICS, INC. (HALO)
Filed: 2026-08-18 AccNo: 0001159036-26-000106 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarWatching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Buys Stock
Read original at benzingaTop 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Read original at benzingaCanaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Read original at benzingaHC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
Read original at benzinga